HCP
Dymista Menu
HCP
 

Dymista® is indicated for the relief of symptoms of moderate to severe seasonal and perennial allergic rhinitis if monotherapy with either intranasal antihistamine or glucocorticoid is not considered sufficient.

Dymista® is an intranasal allergic rhinitis therapy

left left
right right
Dymista® is indicated for the relief of symptoms of moderate to severe seasonal and perennial allergic rhinitis if monotherapy with either intranasal antihistamine or glucocorticoid is not considered sufficient.
Dymista® is an intranasal allergic rhinitis therapy

Current therapy is insufficient for most patients since they continue to experience symptoms when treated (even with multiple therapies).

Dymista® is a intranasal formulation of fluticasone propionate and azelastine hydrochloride.

The recommended daily dose is one spray in each nostril twice a day (morning and evening).

Dymista® is indicated for the relief of symptoms of moderate to severe seasonal and perennial allergic rhinitis if monotherapy with either intranasal antihistamine or glucocorticoid is not considered sufficient.

Dymista® is indicated for the relief of symptoms of moderate to severe seasonal and perennial allergic rhinitis if monotherapy with either intranasal antihistamine or glucocorticoid is not considered sufficient.

UK/DYM/14/0070(1) Date of Prep: February 2017

Login

Log in

CloseClose

Sign in to Dymista

Don't have a Dymista account?

The website you are trying to access is designed for UK Healthcare Professionals only - the content is not designed for the general public.


Are you a UK Healthcare Professional?

Yes No
Why do I need to answer this?

No, I am not a HCP

Sorry, you do not have the authorization to enter this webpage.

Go back Go back
close-icon